Department of Physiatry, Hospital for Special Surgery, New York, New York, USA.
Department of Physical Medicine and Rehabilitation, Weill Cornell Medicine, New York, New York, USA.
PM R. 2023 Mar;15(3):259-264. doi: 10.1002/pmrj.12853. Epub 2022 Jul 12.
Numerous studies have indicated that intra-articular steroid injections to the hip are beneficial for short-term pain relief. However, recent studies have drawn concerns of rapidly progressive osteoarthritis of the hip (RPOH) following intra-articular steroid injections. The prevalence of RPOH following intra-articular steroid injections varies widely in the literature.
To identify the prevalence of RPOH following intra-articular steroid injections, and to compare baseline characteristics between patients with and without RPOH.
Case series.
Tertiary academic hospital.
A total of 924 patients (median [interquartile range; IQR] age: 59 [45-70] years; 579 female) who received an intra-articular hip steroid/anesthetic injection from January 2016 to March 2018 and had available pre- and post-injection imaging (prior to surgical intervention) were included in the study.
Baseline and injection-related data-including demographics, age, body mass index, medical history, laterality, and steroid type-were collected from electronic medical records.
Post-injection RPOH was determined via imaging review by a physiatry fellow, followed by an attending physiatrist and a musculoskeletal radiologist to confirm findings.
The majority of patients received unilateral injections into the hip, and the most common steroids used were triamcinolone and methylprednisolone. Review of pre- and post-injection imaging revealed 26 cases of RPOH, for an overall prevalence of 2.8% (95% confidence interval [CI] 1.9%-4.1%). Compared to those without RPOH, patients with RPOH were significantly older (median age [IQR]: 64 [60-73] vs. 59 [44-70] years, p = .003) and had a shorter duration of symptoms prior to their injections (median [IQR]: 3 vs. 12 [6-36] months, p < .001). Adjusted regression analyses showed that age was associated with greater odds of RPOH (odds ratio [OR], 95% CI: 1.04, 1.01 to 1.07; p = .003).
The prevalence of RPOH following intra-articular steroid injections into the hip was lower than previously reported but still clinically relevant. This should be considered when counseling patients prior to intra-articular hip steroid injections.
许多研究表明,髋关节腔内类固醇注射对短期缓解疼痛有益。然而,最近的研究对髋关节腔内类固醇注射后迅速进展性骨关节炎(RPOH)引起了关注。文献中髋关节腔内类固醇注射后 RPOH 的发生率差异很大。
确定髋关节腔内类固醇注射后 RPOH 的发生率,并比较 RPOH 患者和无 RPOH 患者的基线特征。
病例系列。
三级学术医院。
共纳入 924 名患者(中位年龄[四分位距;IQR]:59[45-70]岁;579 名女性),这些患者于 2016 年 1 月至 2018 年 3 月接受髋关节腔内类固醇/麻醉注射,并在接受注射前和注射后均有影像学检查(在手术干预之前)。
从电子病历中收集基线和注射相关数据,包括人口统计学、年龄、体重指数、病史、侧别和类固醇类型。
通过物理治疗住院医师、主治物理治疗师和肌肉骨骼放射科医生对影像学检查进行回顾,以确定注射后是否发生 RPOH。
大多数患者接受单侧髋关节注射,最常用的类固醇是曲安奈德和甲泼尼龙。对注射前和注射后的影像学检查进行回顾,发现 26 例 RPOH,总体发生率为 2.8%(95%置信区间[CI] 1.9%-4.1%)。与无 RPOH 患者相比,RPOH 患者年龄明显更大(中位年龄[IQR]:64[60-73] vs. 59[44-70]岁,p=0.003),注射前症状持续时间更短(中位[IQR]:3 vs. 12[6-36]个月,p<0.001)。调整后的回归分析显示,年龄与 RPOH 的发生几率更大相关(比值比[OR],95%CI:1.04,1.01 至 1.07;p=0.003)。
髋关节腔内类固醇注射后 RPOH 的发生率低于先前报道,但仍具有临床意义。在为髋关节腔内类固醇注射患者提供咨询时,应考虑这一点。